Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and lowers the price target from $34 to $32.
Oppenheimer Maintains Outperform on UroGen Pharma, Lowers Price Target to $32
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.